Company: RCUS
Filing Date: 2025-10-31
Form Type: 424B5
Source: 0001193125-25-260836
Chunk: 71

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-31
Form: 424B5
Chunk 71
---
 or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above. Unless we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations occur:

| • |     | if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for 
 that global security and we do not appoint another institution to act as depositary within 90 days;             |

| • |     | if we notify any applicable trustee that we wish to terminate that global security; or |

| • |     | if an event of default has occurred with regard to securities represented by that global security and has not 
 been cured or waived.                                                                                         |

The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders. 25

PLAN OF DISTRIBUTION We may sell the securities from time to time pursuant to underwritten public offerings, direct sales to the public, “at-the-market” offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions:

| • |     | at a fixed price or prices, which may be changed; |

| • |     | at market prices prevailing at the time of sale; |

| • |     | at prices related to such prevailing market prices; or |

| • |     | at negotiated prices. |

A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable:

| • |     | the name or names of the underwriters, if any; |

| • |     | the purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive 
 from the sale;                                                                                                  |

| • |     | any options under which underwriters may purchase additional securities from us; |